Clinical ResearchRandomized Controlled Trial of Subcutaneous EPOETIN ALFA (cas 113427-24-0)-epbx Versus EPOETIN ALFA (cas 113427-24-0) in End-Stage Kidney Disease

Add time:08/12/2019    Source:sciencedirect.com

IntroductionThis double-blind, randomized controlled trial compared the safety and efficacy of subcutaneous EPOETIN ALFA (cas 113427-24-0)-epbx, an epoetin alfa biosimilar, with the reference product, epoetin alfa, in hemodialysis patients with end-stage kidney disease and anemia who were receiving epoetin alfa maintenance treatment.

We also recommend Trading Suppliers and Manufacturers of EPOETIN ALFA (cas 113427-24-0). Pls Click Website Link as below: cas 113427-24-0 suppliers

Prev:Enhanced antitumor activitiy of trans(±)-1,2-Diaminocyclo- hexaneglutamatoplatinum(II) formulated with stealth liposome
Next:Preparative synthesis of 2,2-dimethyl-5-(trifluoroacetyl)-1,3-dioxane-4,6-dione (2-trifluoroacetyl Meldrum's acid) and 2,2-dimethyl-6-(trifluoromethyl)-4H-1,3-dioxin-4-one and their synthetic usefulness as (trifluoroacetyl)ketene precursors)